Company Filing History:
Years Active: 2013
Title: The Innovations of Roger Beerli
Introduction
Roger Beerli is a notable inventor based in Adlikon b. Regensdorf, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of human antibodies. With a total of two patents to his name, Beerli's work focuses on addressing critical health issues, including influenza and nicotine addiction.
Latest Patents
One of Beerli's latest patents is for fully human influenza M2 specific antibodies. This invention relates to human antibodies that specifically bind to the influenza M2e antigen. It encompasses individual light- and heavy chains of these antibodies, as well as nucleic acids encoding them and expression vectors for their production. The application of these antibodies is aimed at the treatment and prevention of influenza A virus infections in humans. Another significant patent is for human monoclonal nicotine specific antibodies. This invention involves recombinantly produced human monoclonal antibodies that specifically bind to nicotine. It also includes nucleic acids encoding these antibodies and their use in treating nicotine addiction.
Career Highlights
Throughout his career, Roger Beerli has worked with prominent companies in the biotechnology sector, including Cytos Biotechnology AG and Intercell AG. His experience in these organizations has contributed to his expertise in antibody development and therapeutic applications.
Collaborations
Beerli has collaborated with notable colleagues such as Martin F. Bachmann and Monika Bauer. These partnerships have likely enhanced his research and innovation efforts in the field of biotechnology.
Conclusion
Roger Beerli's contributions to the field of biotechnology through his patents and collaborations highlight his commitment to advancing medical science. His work in developing human antibodies for influenza and nicotine addiction showcases the potential for innovative solutions to pressing health challenges.